| Ytd | -57.36% | |
| 1y | -80.37% |
| Open | 0.52 | Prev Close | 0.52 | Low | 0.39 | High | 0.57 | Mkt Cap | 16.45M |
| Vol | 4.45M | Avg Vol | 3.24M | EPS | -0.58 | P/E | N/A | Forward P/E | -0.77 |
| Beta | 3.35 | Short Ratio | 3.96 | Inst. Own | 24.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 0.50 | 200-d Avg | 0.98 | 1yr Est | 21.00 |
CRIS News
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T
Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular se
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-494
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'